considerations for analyzing targeted ngs data brca tim hague,cto

30
Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO Omixon Workshops Considerations for Analyzing Targeted NGS Data - BRCA Tim Hague, CEO

Upload: harriet-lambert

Post on 22-Dec-2015

219 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Considerations for Analyzing Targeted NGS Data

BRCA

Tim Hague,CTO

Omixon WorkshopsConsiderations for Analyzing Targeted NGS Data - BRCATim Hague, CEO

Page 2: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

BRCA 1 and 2 are best known as 'cancer susceptibility' genes

Actually the proteins repair damage in DNA

Large number of known deleterious mutations

Disproportionate number of indels

Introduction

Page 3: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Mary-Claire King discovered BRCA1 and BRCA2, published the function

Myriad Genetics won the patent

History

Page 4: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Indel size (nt)

Distribution of Known BRCA1 Deletions >3 bp

Page 5: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Dominuque StoppaLyonnet at Curie Institute

„Large scale deletions could account for as many as one-third of all BRCA1 mutations in some populations”

Page 6: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

BRCA are tumor suppressor genes. 82% lifetime chance of developing breast/ovarian cancer

Science 2004, 306:2187-2191

>1,500 deleterious BRCA mutations

17 kbp coding region with mutation rate of: 1/2000

NGS-based BRCA screening Leeds UK, Newgene UK, Ghent Belgium

DIY genetic test published by Salzberg

Page 7: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

82% chance of cancer

>90% chance of being false positive/ negative

Page 8: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO
Page 9: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

False negatives must be avoided Precision of both sequencing data and the

data analysis is key Looking for indels – indel detection

abilities are a key criterion Repeats are also an issue in BRCA region

What kind of NGS data?

Page 10: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

BRCA Repeats

Page 11: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Homopolymer errors look like small indels and can cause noise

Problem for: Roche 454

Ion Torrent

Homopolymer Errors

Page 12: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Read length is a limiting factor for insertion detection

When searching for indels, long reads can help. Long reads can also help with repeats

Roche 454 have the longest reads

Long Reads

Page 13: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Real Examples With Roche 454 Data

Page 14: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Real Examples With Roche 454 Data

Page 15: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Paired reads can also help to increase effective 'read length'

Illumina MiSeq now has 2x250bp protocol

Paired Reads

Page 16: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO
Page 17: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Compare 9 open source and commercial NGS analysis softwares

In silico test with mutated reference BRCA gene

2211 known BRCA variants

1341 SNOs, 320 insertions and 551 deletions

Full GATK pipeline used for variant call, including quality recalibration and indel realignment

Page 18: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO
Page 19: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO
Page 20: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO
Page 21: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Overall Sensitivity:

99.2% Paired End

94.5% Single End

SNPs Found:

99.5% PE

99.5% SE

Deletions Found:

98.5% PE

85.5% SE

Insertions Found:

99.4% PE

89.4% SE

BWA

Page 22: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

False Negatives :

17 Paired End

121 Single End

False Positives:

23 PE

168 SE

The longest (60bp+) deletions were not found, either with PE or SE data

BWA

Page 23: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Indel Sizes – BWA Single End

Page 24: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Indel Sizes – BWA Paired End

Page 25: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Most other alignment tools showed a similar trend – much better results overall with Paired data

Only two of the tools tested found the longest deletions, even with Paired data

Other Tools

Page 26: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Much better for reliable variant detection than equivalent length single reads

Provided much better coverage in the BRCA region (spanning small repeats)

If available, paired reads should be preferred

Paired Reads - Conclusions

Page 27: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Not all tools are good at finding indels

Burrows Wheeler based aligners can't find indels beyond a few base pairs in single reads, but can make better use of paired data – if indel realignment is also used

They still can't detect the longest indels (there is just a gap in coverage)

If indel detection is required, an indel sensitive tool should be used

Indel Detection - Conclusions

Page 28: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

None of the alignment tools found all the variants It will almost certainly require the same data to be

analyzed with more than one tool, to get sufficiently accurate results

Overall - Conclusions

Page 29: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Contact

Tim Hague, CEO

Omixon Biocomputing Solutions

[email protected]

+36 70 318 4878

Page 30: Considerations for Analyzing Targeted NGS Data BRCA Tim Hague,CTO

Download our Omixon Target™ Evaluation Version

Today

OMIXON.COM